Literature DB >> 18412227

Rosacea treatment using the new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser.

Eric F Bernstein1, Albert Kligman.   

Abstract

BACKGROUND AND OBJECTIVES: Rosacea results from sun-induced hyper-vascularity of exposed facial skin, often accompanied by acneiform papules and pustules. The pulsed-dye laser has an unparalleled safety record and emits an ideal wavelength for treating the abnormal vessels that occur in rosacea patients. In this study we investigate the ability of the long pulse-duration pulsed-dye laser to improve rosacea. STUDY DESIGN/
MATERIALS AND METHODS: Twenty subjects with rosacea were treated with the high-energy, long pulse-duration pulsed-dye laser. An elliptical spot and long pulse-duration was used to spot-treat linear telangiectasias, while a circular spot and short pulse-duration was used to treat the entire face. Improvement was determined by blinded evaluation of photographs and by the treating physician's subjective evaluation, before and 8 weeks following the final treatment.
RESULTS: The average rosacea score as estimated by the treating physician decreased from 2.7+/-1.1 to 1.4+ 0.7 (mean+SD) on a 0-6 scale with 0 representing no rosacea and 6 representing the most severe rosacea (P<0.001 level). The average rosacea score as rated by blinded physician observers scoring digital photos was 2.3+/-1.3 before treatment and 1.4+/-0.9 8 weeks following treatment, using a 0 (mild) to 6 (severe) scale.
CONCLUSIONS: The high-energy, long pulse-duration pulsed-dye laser improves rosacea with a very favorable safety profile, and less purpura than resulted from earlier generation pulsed-dye lasers.

Entities:  

Mesh:

Year:  2008        PMID: 18412227     DOI: 10.1002/lsm.20621

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  12 in total

1.  [Non-pharmacologic management of rosacea].

Authors:  C Borelli; H C Korting
Journal:  Hautarzt       Date:  2011-11       Impact factor: 0.751

Review 2.  [Rosacea 2009 : new advances in pathophysiology, clinical staging and therapeutic strategies].

Authors:  A Sobottka; P Lehmann
Journal:  Hautarzt       Date:  2009-12       Impact factor: 0.751

Review 3.  Laser and light-based therapies in the management of rosacea: an updated systematic review.

Authors:  Husein Husein-ElAhmed; Martin Steinhoff
Journal:  Lasers Med Sci       Date:  2021-01-03       Impact factor: 3.161

4.  Treatment Outcomes of Long-Pulsed Nd: YAG Laser for Two Different Subtypes of Rosacea.

Authors:  Ekin Mese Say; Gokhan Okan; Gonca Gökdemir
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

Review 5.  Rosacea Management.

Authors:  Manal Abokwidir; Steven R Feldman
Journal:  Skin Appendage Disord       Date:  2016-05-18

Review 6.  Interventions for rosacea.

Authors:  Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland
Journal:  Cochrane Database Syst Rev       Date:  2015-04-28

Review 7.  Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features.

Authors:  Giuseppe Micali; Peter Arne Gerber; Francesco Lacarrubba; Gregor Schäfer
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

8.  Update on the management of rosacea.

Authors:  Allison P Weinkle; Vladyslava Doktor; Jason Emer
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-04-07

9.  Emotional benefit of cosmetic camouflage in the treatment of facial skin conditions: personal experience and review.

Authors:  Lauren L Levy; Jason J Emer
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-11-01

10.  A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea.

Authors:  Pooja Sodha; Amanda Suggs; Girish S Munavalli; Paul M Friedman
Journal:  Lasers Surg Med       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.